Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine
storm. Therefore, treatment with immunomodulating agents should be initiated as soon as …

Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the
inflammatory response and control the symptoms of severe coronavirus disease 2019 …

Purpose: Tocilizumab is associated with positive outcomes in severe COVID-19. We wanted
to describe the characteristics of nonresponders to treatment. Methods: This was a …

Introduction Since the beginning of the COVID-19 pandemic, the repurposing of medicines
has been pursued to find interventions effective in preventing fatal outcome of the disease …

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …

Background COVID-19 is a new disease that appeared in December 2019. Millions of
people have been infected and died from this infection. Until today, the pathophysiology and …

Introduction COVID-19 caused by severe acute respiratory syndromecoronavirus 2 (SARS-
CoV2) has resulted in many deaths worldwide. The pathophysiology of COVID-19 involves …

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a …

Abstract Severe COVID-19 (coronavirus disease 2019) is associated with elevated
inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …